- Home
- TIL vs OPP Comparison
TIL vs OPP Comparison
Compare TIL & OPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- OPP
- Stock Information
- Founded
- TIL 2018
- OPP 2010
- Country
- TIL United States
- OPP United States
- Employees
- TIL N/A
- OPP N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- OPP Finance/Investors Services
- Sector
- TIL Health Care
- OPP Finance
- Exchange
- TIL Nasdaq
- OPP Nasdaq
- Market Cap
- TIL 171.7M
- OPP 204.1M
- IPO Year
- TIL 2021
- OPP N/A
- Fundamental
- Price
- TIL $15.46
- OPP $8.19
- Analyst Decision
- TIL Buy
- OPP
- Analyst Count
- TIL 5
- OPP 0
- Target Price
- TIL $114.00
- OPP N/A
- AVG Volume (30 Days)
- TIL 78.2K
- OPP 108.0K
- Earning Date
- TIL 05-09-2025
- OPP 01-01-0001
- Dividend Yield
- TIL N/A
- OPP 14.41%
- EPS Growth
- TIL N/A
- OPP N/A
- EPS
- TIL N/A
- OPP N/A
- Revenue
- TIL N/A
- OPP N/A
- Revenue This Year
- TIL N/A
- OPP N/A
- Revenue Next Year
- TIL N/A
- OPP N/A
- P/E Ratio
- TIL N/A
- OPP N/A
- Revenue Growth
- TIL N/A
- OPP N/A
- 52 Week Low
- TIL $9.62
- OPP $7.26
- 52 Week High
- TIL $92.00
- OPP $8.83
- Technical
- Relative Strength Index (RSI)
- TIL 44.19
- OPP 39.61
- Support Level
- TIL $14.96
- OPP $8.00
- Resistance Level
- TIL $18.71
- OPP $8.25
- Average True Range (ATR)
- TIL 1.80
- OPP 0.21
- MACD
- TIL 0.09
- OPP -0.02
- Stochastic Oscillator
- TIL 46.32
- OPP 35.00
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.